Bevacizumab
Basic Information
- Bevacizumab also goes by Avastin
- Is an FDA approved treatment for colorectal cancer
- Is an investigational recombinant humanized antibody to vascular endothelial cell growth factor; designed to bind to and inhibit Vascular Endothelial Growth Factor (VEGF), a protein that plays a critical role in tumor angiogenesis (the formation of new blood vessels to the tumor) and maintenance of established tumor blood vessels (source)
- Seems to have been used successfully in colorectal and kidney cancers
- NCI/Cancer.gov information page on bevacizumab
- More information
- Article which lists differences between bevacizumab and 2C3 (made by Peregrine)
Research Results
- 2002 abstract which states that sarcomas have a high amount of VEGF
Current Clinical Trials
There are several trials open to sarcoma patients that involve Bevacizumab. Click here to see them.